Dr. Heidi Wang received her Ph.D. from University of Notre Dame in Indiana, USA. She is the Vice President and Head of Global Regulatory Science-China and Hong Kong, Bristol-Myers Squibb Company (BMS). She has led the teams to obtain three first-in-class drug approvals in China, including HCV direct acting agents (Daklinza and Sunvepra) and an Immuno-Oncology PD-1 inhibitor (Opdivo). Prior to China, Dr. Wang had over 20 years of experience working in BMS US headquarter with responsibilities in the US and 38 other countries.
Arena’s business-to-business events offer a myriad of opportunities for sponsors and exhibitors to drive their businesses forward.
Our sponsorship packages help companies educate ther target market on key industry issues and spread brand awareness throughout the
If you want to discuss how we can help you generate leads and add-value to your corporate and brand image please contact:
+44 (0)20 7936 6948